Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.56 |
| ▸ | PDE5A | O76074 | 6/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711172 | 0.87 | PRMT5 (0.60) | AURKAPDE5APRMT5NPY5RPDE4A | |
| SCHEMBL9635813 | 0.81 | AURKA (0.54) | AURKAPDE5APRMT5NPY5RPDE4A | |
| SCHEMBL711302 | 0.81 | PRMT5 (0.57) | AURKAPDE5APRMT5NPY5RPDE4A | |
| SCHEMBL11155883 | 0.79 | AURKA (0.67) | AURKAPDE5APRMT5METAP1METAP2 | |
| SCHEMBL711692 | 0.76 | PRMT5 (0.56) | AURKAPDE5APRMT5NPY5RPDE4A | |
| SCHEMBL711966 | 0.74 | PRMT5 (0.67) | AURKAPDE5APRMT5PDE4APDE4B | |
| SCHEMBL2668291 | 0.73 | PRMT5 (0.65) | AURKAPDE5APRMT5PDE4APDE4B | |
| SCHEMBL9634492 | 0.72 | AURKA (0.63) | AURKAPDE5APRMT5NPY5RPDE2A | |
| SCHEMBL2668280 | 0.72 | PRMT5 (0.54) | AURKAPDE5APRMT5NPY5RPDE4A | |
| SCHEMBL10744129 | 0.72 | AURKA (0.70) | AURKAPDE5APRMT5PDE2AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | AURKA 1618/4885PDE5A 593/4885PRMT5 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.